College of Medicine, Mayo Clinic, 13400 E Shea Blvd, Scottsdale, AZ 85259, USA.
Osteoporos Int. 2012 Jan;23(1):365-75. doi: 10.1007/s00198-011-1778-8. Epub 2011 Sep 9.
Studies on use of selective serotonin reuptake inhibitors (SSRIs) and risk of fracture have yielded inconsistent results. This meta-analysis, which pooled results from 13 qualifying cohort and case-control studies, found that SSRIs were associated with a significantly increased risk of fractures.
This study was conducted to assess whether people who take SSRIs are at an increased risk of fracture.
We conducted a meta-analysis of observational studies. Relevant studies published by February 2010 were identified through literature searches using MEDLINE (from 1966), EMBASE (from 1988), PsycINFO (from 1806), and manual searching of reference lists. Only cohort or case-control studies that examined the association of SSRIs and risk of fracture and bone loss were included. Data were abstracted independently by two investigators using a standardized protocol; disagreements were resolved by consensus. Random effects models were used for pooled analysis due to heterogeneity in the studies.
Thirteen studies met inclusion criteria. Overall, SSRI use was associated with a significantly increased risk of fracture (relative risk, RR, 1.72; 95% CI [1.51, 1.95]; P < 0.001). An increased fracture risk associated with SSRIs also was observed in the three studies that adjusted for bone mineral density (RR, 1.70; 95% CI [1.28, 2.25]; P < 0.001) and in the four studies that adjusted for depression (RR 1.74; 95% CI [1.28, 2.36]; P < 0.001). SSRI use was not associated with bone loss in the two cohort studies of women (P = 0.29). The overall association between SSRI use and fracture risk was weaker (RR, 1.40; 95% CI [1.22, 1.61]), though still significant (P < 0.001) in analyses that accounted for apparent publication bias.
Use of SSRIs is associated with increased risk of fracture. The SSRIs may exert an increased risk of fracture independent of depression and bone mineral density.
关于选择性 5-羟色胺再摄取抑制剂(SSRIs)的使用与骨折风险的研究结果并不一致。本项荟萃分析汇总了 13 项合格的队列研究和病例对照研究的结果,发现 SSRIs 与骨折风险显著增加相关。
本研究旨在评估 SSRIs 是否会增加骨折风险。
我们对观察性研究进行了荟萃分析。通过使用 MEDLINE(自 1966 年起)、EMBASE(自 1988 年起)、PsycINFO(自 1806 年起)和手动检索参考文献列表,检索到 2010 年 2 月前发表的相关研究。仅纳入了评估 SSRIs 与骨折和骨丢失风险相关性的队列研究或病例对照研究。两位研究者独立使用标准化方案提取数据;如果存在分歧,则通过协商解决。由于研究之间存在异质性,因此使用随机效应模型进行汇总分析。
共有 13 项研究符合纳入标准。总体而言,SSRIs 的使用与骨折风险显著增加相关(相对风险,RR,1.72;95%置信区间[1.51,1.95];P<0.001)。在 3 项调整了骨密度的研究(RR,1.70;95%置信区间[1.28,2.25];P<0.001)和 4 项调整了抑郁的研究(RR,1.74;95%置信区间[1.28,2.36];P<0.001)中,SSRIs 与骨折风险的相关性也得到了证实。在两项针对女性的队列研究中,SSRIs 的使用与骨丢失无关(P=0.29)。在考虑到明显的发表偏倚的分析中,SSRIs 使用与骨折风险之间的总体相关性较弱(RR,1.40;95%置信区间[1.22,1.61]),但仍具有统计学意义(P<0.001)。
SSRIs 的使用与骨折风险增加相关。SSRIs 可能会增加骨折风险,而与抑郁和骨密度无关。